PubRank

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Clinical Trial ID NCT01820364

PubWeight™ 16.66‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01820364

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014 1.55
2 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
3 Beyond BRAF: where next for melanoma therapy? Br J Cancer 2014 1.26
4 Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013 1.12
5 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015 0.99
6 Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene 2015 0.98
7 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
8 Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene 2015 0.90
9 Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther 2014 0.88
10 Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. BMC Cancer 2015 0.82
11 Resistance to Raf inhibition in cancer. Drug Discov Today Technol 2014 0.79
12 Genotyping of cutaneous melanoma. Chin Clin Oncol 2014 0.78
13 Targeted Therapies in Melanoma: Translational Research at Its Finest. J Invest Dermatol 2015 0.78
14 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
15 MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther 2015 0.77
16 Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 2016 0.76
17 Complexity of FGFR signalling in metastatic urothelial cancer. J Hematol Oncol 2015 0.76
18 Other targeted drugs in melanoma. Ann Transl Med 2015 0.75
Next 100